Health Care Sector Equities Coverage -- Research on Johnson and Johnson, Medicines Co., Merck, and Novo Nordisk - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Health Care Sector Equities Coverage -- Research on Johnson and Johnson, Medicines Co., Merck, and Novo Nordisk

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Investor-Edge

Editor Note: For more information about this release, please scroll to bottom.

LONDON, June 13, 2014 /PRNewswire/ --

The US markets on Thursday, June 12, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the session 0.71% lower at 1,930.11. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 688.58, down 0.56%, whereas the index has advanced 1.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Johnson & Johnson (NYSE: JNJ), The Medicines Co. (NASDAQ: MDCO), Merck & Co. Inc. (NYSE: MRK) and Novo Nordisk (NYSE: NVO). Free technical research on JNJ, MDCO, MRK and NVO can be downloaded upon signing up at:

http://www.investor-edge.com/3748-register

On Thursday, shares in Johnson & Johnson fluctuated between $102.51 and $103.21 before ending the session 0.76% lower at $102.53. The stock reported a trading volume of 5.93 million shares, below its three months average volume of 7.49 million shares. Shares of the company traded at a PE ratio of 18.18. Johnson & Johnson's shares have fallen by 0.67% in the previous three trading sessions, while the stock has advanced 2.00% in the last one month and 11.94% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $100.32 and $93.83, respectively. Moreover, shares of Johnson & Johnson have a Relative Strength Index (RSI) of 65.10. Sign up today to read free research on JNJ at:

http://www.investor-edge.com/3748-JNJ-13Jun2014.pdf

The Medicines Co.'s stock edged 0.78% lower, to close the day at $28.04. The stock recorded a trading volume of 0.43 million shares, below its three months average volume of 0.91 million shares. The company shares oscillated between $27.90 and $28.50 during the session. Over the last three trading sessions and since the start of this year, the Medicines Co.'s shares have lost 2.06% and 27.40%, respectively. However, the stock has gained 8.26% over the past one month. The stock is trading above its 50-day moving average of $26.25, while the 50-day moving average is below the Medicines Co.'s 200-day moving average of $32.17. Additionally, the stock traded at a PE ratio of 43.83 and has an RSI of 58.09. Sign up today to read free research on MDCO at:

http://www.investor-edge.com/3748-MDCO-13Jun2014.pdf

On Thursday, shares in Merck & Co. Inc. recorded a trading volume of 9.56 million shares, lower than its three months average volume of 10.45 million shares. The stock ended the day at $58.30, which was 0.12% below its previous day's closing of $58.81, and registered an intraday range of $58.06 and $58.72. Shares of the company traded at a PE ratio of 16.75. Merck & Co. Inc.'s stock has gained 0.62% in the previous three trading sessions, 5.44% in the last one month, and 16.48% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $56.89 and $52.06, respectively. Furthermore, shares of Merck & Co. Inc. have an RSI of 65.04. Sign up today to read free research on MRK at:

http://www.investor-edge.com/3748-MRK-13Jun2014.pdf

Novo Nordisk's stock finished the Thursday's session 2.41% higher at $45.49. A total of 1.06 million shares were traded, which was close to its three months average volume of 1.13 million shares. The stock vacillated between $45.20 and $45.58 during the session. Over the previous three trading sessions and over the last one month, Novo Nordisk's shares have advanced 5.30% and 3.62%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 23.11%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $43.69 is greater than its 200-day moving average of $39.28. Novo Nordisk's stock has an RSI of 61.46. Sign up today to read free research on NVO at:

http://www.investor-edge.com/3748-NVO-13Jun2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.investor-edge.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.